Identification of surface-associated antigens for tumor diagnosis and therapy
The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
1. A method of detecting expression of a tumor-associated antigen in a biological sample isolated from a patient, which method comprises
detection of a nucleic acid of SEQ ID NO:13, which codes for the tumor-associated antigen wherein the detection comprises
(i) contacting nucleic acids isolated from the biological sample with a probe prepared by amplification with a primer set under conditions that allow the probe to hybridize to the nucleic acid within the sequence of SEQ ID NO: 13, and
(ii) detecting a complex formed between the probe and the nucleic acid of SEQ ID NO:13 from the biological sample
wherein the biological sample is isolated from tissue selected from the group consisting of esophagus, pancreas, prostate, thyroid, nasal tissue, lymph tissue, and blood, and
wherein the primer set comprises at least two primers consisting of SEQ ID NO: 15 and SEQ ID NO: 16.
2. The method as claimed in claim 1 , in which the tumor-associated antigen comprises the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, and SEQ ID NO:290.
3. The method as claimed in claim 1 , wherein the tumor antigen is associated with a cancer selected from the group consisting of prostate cancer, esophageal cancer, pancreatic cancer, head and neck cancer, and leukemia.
4. A method of detecting expression of a tumor-associated antigen, which method comprises detection of a nucleic acid which codes for the tumor-associated antigen in a biological sample isolated from a patient, said tumor-associated antigen encoded by the nucleic acid of SEQ ID NO: 13,
wherein the detection comprises:
i) contacting nucleic acids isolated from the biological sample with a primer set under conditions which amplifies the nucleic acids within the sequence of SEQ ID NO: 13 from the biological sample, and
ii) detecting the amplified nucleic acids
wherein the biological sample is isolated from tissue selected from the group consisting of esophagus, pancreas, prostate, thyroid, nasal tissue, lymph tissue, and blood, and
wherein the primer set comprises at least two primers consisting of SEQ ID NO: 15 and SEQ ID NO: 16.
5. The method as claimed in claim 4 , in which the tumor-associated antigen comprises the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, and SEQ ID NO:290.
6. The method as claimed in claim 4 , wherein the tumor antigen is associated with a cancer selected from the group consisting of prostate cancer, esophageal cancer, pancreatic cancer, head and neck cancer, and leukemia.
7. A method of diagnosing a cancer that expresses a tumor-associated antigen, which method comprises
detection of a nucleic acid of SEQ ID NO:13, which codes for the tumor-associated antigen in a biological sample isolated from a patient wherein the detection comprises,
(i) contacting nucleic acids isolated from the biological sample with a probe prepared by amplification with a primer set under conditions that allow the probe to hybridize to the nucleic acid within the sequence of SEQ ID NO: 13, and
(ii) detecting a complex formed between the probe and the nucleic acid of SEQ ID NO:13 from the biological sample,
wherein the primer set comprises at least two primers consisting of SEQ ID NO: 15 and SEQ ID NO: 16.
8. The method as claimed in claim 7 , wherein the cancer is selected from the group consisting of prostate cancer, esophageal cancer, pancreatic cancer, head and neck cancer, and leukemia.